beta

CFRX

ContraFect Corp.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

ContraFect Corp. is a clinical stage biotechnology company, which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Market Cap: 135 Million

Primary Exchange: NASDAQ

Website: http://www.contrafect.com

Shares Outstanding: 27.1 Million

Float: 21.2 Million

Dividend: (%)

Beta: 1.01491218223273

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 1791 trading days

From: 2015-04-13 To: 2020-02-03

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud